Neurocutaneous disorders, also known as phakomatoses, are a wide group of genetic conditions that affect the nervous system, skin, eyes, and other organs, including the kidneys, heart, immune system, and bones. These disorders are caused by abnormalities in the embryonic ectoderm, which explains the involvement of the nervous system and the skin.
Neurocutaneous disorders include neurofibromatosis type 1, tuberous sclerosis complex, Sturge-Weber syndrome, hypomelanosis of Ito, ataxia-telangiectasia, and von Hippel-Lindau disease. Patients often present with distinctive cutaneous manifestations, such as café-au-lait spots in neurofibromatosis or facial angiofibromas in tuberous sclerosis.
Neurological involvement can include seizures, intellectual disability, developmental delays,motor deficit, and a predisposition to tumors in both the nervous system and other parts of the body. Imaging studies, particularly MRI, play a key role in identifying structural abnormalities such as cortical tubers, subependymal nodules, or leptomeningeal angiomas. Neurocutaneous disorders are inherited either in an autosomal dominant pattern or are caused by sporadic mutations.
Management is typically multidisciplinary, involving specialists such as neurologists, dermatologists, ophthalmologists, immunologists, and, sometimes, surgeons to address tumor growth or vascular complications. Ongoing monitoring is essential to early detection of complications such as tumors, neurological deterioration, or exacerbated skin lesions. Improvements in genetic testing and molecular diagnostics have provided earlier diagnosis, individualized management, and genetic counseling.
